| Trial ID: | L2411 |
| Source ID: | NCT00799448
|
| Associated Drug: |
Repaglinide
|
| Title: |
Comparison of Efficacy and Safety of Repaglinide Combined With Insulin NPH Versus Biphasic Human Insulin 30 Alone in Inadequately Controlled Subjects With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: repaglinide|DRUG: biphasic human insulin 30|DRUG: insulin NPH
|
| Outcome Measures: |
Primary: HbA1c, after 20 weeks of treatment | Secondary: Fasting blood glucose (FBG)|Incidence of hypoglycaemic episodes|Adverse events
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
40
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2003-09-16
|
| Completion Date: |
2004-09-20
|
| Results First Posted: |
|
| Last Update Posted: |
2017-02-20
|
| Locations: |
Novo Nordisk Investigational Site, Athens, 15127, Greece
|
| URL: |
https://clinicaltrials.gov/show/NCT00799448
|
